Introduction {#s001}
============

The World Health Organization has declared antimicrobial resistance a global emergency and the development of new antimicrobials as a priority.^[@B1]^ Carbapenem-resistant *Enterobacterales*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* are considered "critical" pathogens.^[@B1]^ The spread of multidrug-resistant Gram-negative pathogens has spurred the development of novel and potentially therapeutic agents. Next-generation aminoglycosides and β-lactamase inhibitors that have been recently brought into clinical practice are welcomed additions to our therapeutic armamentarium; however, resistance to these agents may limit their utility. For example, the diazabicyclooctanes are a new class of β-lactamase inhibitors that are active against many pathogens carrying serine β-lactamases.^[@B2]^ However, the currently available agents are not therapeutic options for isolates possessing metallo-β-lactamases. Clearly, alternative approaches are needed.

Cefiderocol (previously S-649266) is novel siderophore cephalosporin with a catechol moiety at position 3 of the cephalosporin side chain. This moiety facilitates formation of chelated complexes with iron and crosses the outer membrane of Gram-negative bacilli through active iron transporters.^[@B3]^ Several studies have shown potent *in vitro* activity of cefiderocol against *Enterobacterales*, *P. aeruginosa*, and *A. baumannii*, including isolates resistant to carbapenems.^[@B4]^ The spectrum of activity of cefiderocol includes isolates harboring a wide range of carbapenemases, including serine (KPC, OXA-type) and metallo (VIM, IMP, NDM) β-lactamases.^[@B7]^ Finally, in one clinical trial cefiderocol was comparable with imipenem--cilastatin for treatment of complicated urinary tract infections owing to carbapenem-susceptible pathogens.^[@B14]^

In this report we examine the *in vitro* activity of cefiderocol against *Enterobacterales*, *P. aeruginosa*, and *A. baumannii* endemic to New York City.

Materials and Methods {#s002}
=====================

Isolates {#s003}
--------

Clinical isolates of *Enterobacterales*, *P. aeruginosa*, and *A. baumannii* underwent susceptibility testing. Three groups of *Enterobacterales* were analyzed, including (1) 2558 single-patient isolates of *Escherichia coli*, *Enterobacter* spp. (included in this group was *Klebsiella aerogenes*), and *Klebsiella pneumoniae* gathered during a 3-month surveillance study involving seven hospitals in Brooklyn, New York in 2017; (2) 111 carbapenem-resistant (and KPC-possessing) isolates of *K. pneumoniae* gathered from a similar surveillance study performed in 2013--2014; and (3) 34 well-characterized isolates of *K. pneumoniae*.^[@B15]^ For the last group, the presence of β-lactamases and genetic expression of *bla*~KPC~, *ompK35*, *ompK36*, and *acrB* were previously determined.^[@B17]^ Multilocus sequence typing was performed on select isolates of *K. pneumoniae* according to established protocols.^[@B18]^

For *P. aeruginosa* and *A. baumannii*, a similar three groups of isolates were analyzed. These groups included (1) 269 single-patient isolates of *P. aeruginosa* and 46 isolates of *A. baumannii* collected during the 2017 surveillance study, (2) carbapenem-resistant isolates of *P. aeruginosa* (*n* = 130) and *A. baumannii* (*n* = 78) gathered during a 2013--2014 surveillance study, and (3) 33 isolates of *P. aeruginosa* and 34 isolates of *A. baumannii* that were previously characterized for mechanisms of antimicrobial resistance.^[@B19]^ For *P. aeruginosa*, the presence of β-lactamases and genetic expression of *ampC*, *oprD*, *mexA*, *mexC*, *mexE*, and *mexX* were analyzed.^[@B20]^ For the *A. baumanii* isolates, the presence of β-lactamases and genetic expression of *ampC*, *oxa51*, *adeB*, and *abeM* were determined, as previously described.^[@B21]^

Susceptibility testing {#s004}
----------------------

Cefiderocol minimum inhibitory concentrations (MICs) were performed in iron-depleted cation-adjusted Mueller--Hinton broth.^[@B22]^ MICs for the remaining antibiotics were performed by the agar dilution method with Mueller--Hinton agar according to established CLSI methods.^[@B23]^ Susceptibility rates were determined using CLSI criteria; for cefiderocol, the provisional breakpoint of 4 mg/L was used.^[@B24]^ Control strains included *E. coli* ATCC 25922 and 35218 and *P. aeruginosa* ATCC 27853.

Statistical analysis using the two-tailed Student\'s *t*-test and multiple linear regression were used to compare MICs with characterized mechanisms of resistance. A value of *p* \< 0.05 was considered significant.

Results {#s005}
=======

Enterobacterales {#s006}
----------------

Among the surveillance isolates gathered in 2017 ([Table 1](#tb1){ref-type="table"}), all *E. coli* isolates (*n* = 1869) had cefiderocol MICs ≤2 mg/L. Among the ceftazidime-resistant isolates (*n* = 141), the MIC~50~/MIC~90~ values were 0.5/2 mg/L, which were fourfold higher compared with the values of the ceftazidime-susceptible isolates (0.12/0.5 mg/L). The mean cefiderocol MIC was higher in the group resistant to ceftazidime vs. the isolates susceptible to ceftazidime (0.55 ± 0.51 vs. 0.16 ± 0.17 mg/L, *p* \< 0.001). Similarly, all the *Enterobacter* spp. (*n* = 172, including 58 isolates of *K. aerogenes* and 104 isolates of *Enterobacter cloacae*) had cefiderocol MICs ≤2 mg/L. For the *Enterobacter* isolates that were resistant to ceftazidime (*n* = 38), the MIC~50~/MIC~90~ values for cefiderocol were 0.25/1 mg/L, which were twofold higher than those values of the ceftazidime-susceptible isolates (0.12/0.5 mg/L). In addition, the 18 isolates of *Enterobacter* that were nonsusceptible to piperacillin/tazobactam (and presumably AmpC hyperproducers) had MIC~50~/MIC~90~ values for cefiderocol that were twofold higher than that of the susceptible isolates (0.25/1 vs. 0.12/0.5 mg/L, respectively).

###### 

Susceptibility Results Involving Enterobacteriaceae from the 2017 Surveillance Collection and the 2013--2014 Carbapenem-Resistant Collection

                                                          MIC~50~      MIC~90~   Range                   
  ------------------------------------------------------- ------------ --------- ---------------------- ------
  2017 surveillance isolates                                                                            
   *Escherichia coli* (*n* = 1869)                                                                      
    Cefiderocol                                           0.12         0.5       ≤0.03 to 2             100
    Piperacillin/tazobactam                               2/4          4/4       ≤0.25/4 to \>128/4     99
    Ceftriaxone                                           ≤0.06        16        ≤0.06 to \>32          88
    Ceftazidime                                           0.25         2         ≤0.12 to \>32          92
    Meropenem                                             ≤0.12        ≤0.12     ≤0.12 to 4             99.9
    Gentamicin                                            1            \>16      ≤0.25 to \>16          86
    TMP/SMX                                               ≤0.25/4.75   \>4/76    ≤0.25/4.75 to \>4/76   64
    Ciprofloxacin                                         ≤0.12        \>4       ≤0.12 to \>4           67
   *Enterobacter* spp. (*n* = 172)                                                                      
    Cefiderocol                                           0.12         0.5       ≤0.03 to 1             100
    Piperacillin/tazobactam                               4/4          32/4      ≤0.25/4 to \>128/4     90
    Ceftriaxone                                           0.25         32        ≤0.06 to \>32          81
    Ceftazidime                                           0.5          32        ≤0.12 to \>32          83
    Meropenem                                             ≤0.12        ≤0.12     ≤0.12 to \>8           98
    Gentamicin                                            1            1         ≤0.25 to \>16          94
    TMP/SMX                                               ≤0.25/4.75   \>4/76    ≤0.25/4.75 to \>4/76   84
    Ciprofloxacin                                         ≤0.12        1         ≤0.12 to \>4           91
   *Klebsiella pneumoniae* (*n* = 517)                                                                  
    Cefiderocol                                           0.12         0.5       ≤0.03 to 2             100
    Piperacillin/tazobactam                               4/4          8/4       ≤0.25/4 to \>128/4     96
    Ceftriaxone                                           ≤0.06        \>32      ≤0.06 to \>32          83
    Ceftazidime                                           0.25         16        ≤0.12 to \>32          84
    Meropenem                                             ≤0.12        ≤0.12     ≤0.12 to \>8           96
    Gentamicin                                            0.5          8         ≤0.25 to \>16          89
    TMP/SMX                                               ≤0.25/4.75   \>4/76    ≤0.25/4.75 to \>4/76   79
    Ciprofloxacin                                         ≤0.12        \>4       ≤0.12 to \>4           85
  2013--2014 Carbapenem-resistant surveillance isolates                                                 
   *K. pneumoniae* (*n* = 111)                                                                          
    Cefiderocol                                           1            2         ≤0.03 to 4             100

TMP/SMX, trimethoprim sulfamethoxazole.

All the 2017 surveillance isolates of *K. pneumoniae* (*n* = 517) had cefiderocol MICs of ≤2 mg/L, including 19 isolates with *bla*~KPC~. Of the 19 *bla*~KPC~-possessing isolates, 12 belonged to ST258, two belonged to ST340, and one each belonged to ST45, ST327, ST584, ST3359, and ST3369. Compared with the ceftazidime-susceptible isolates, the ceftazidime-resistant isolates (but lacking *bla*~KPC~) had greater mean cefiderocol MICs (0.43 ± 0.46 vs. 0.21 ± 0.20 mg/L, *p* \< 0.001) and MIC~50~/MIC~90~ values (0.25/1 vs. 0.12/0.5 mg/L). For the 111 KPC-possessing isolates gathered in 2013--2014, the MIC~50~/MIC~90~ values for cefiderocol were 1 and 2 mg/L, and all had an MIC of ≤4 mg/L.

There were 34 previously characterized isolates of *K. pneumoniae*, including 14 with the carbapenemase KPC ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). The mean cefiderocol MIC for isolates (*n* = 10) that did not have an extended-spectrum beta-lactamase (ESBL) or KPC β-lactamase was 0.24 ± 0.18 mg/L (range = 0.06--0.5 mg/L). The mean cefiderocol MIC for isolates (*n* = 10) that possessed only an ESBL (*bla*~SHV~) was 1.1 mg/L ± 1.09 mg/L (range = 0.25--4 mg/L; *p* = 0.04 compared with isolates lacking an ESBL). The one isolate in this group with an MIC = 4 mg/L also possessed an AmpC-type (ACT-1) enzyme. Four isolates with *bla*~KPC~ but without an ESBL had cefiderocol MICs of 0.5--1 mg/L (mean 0.875 mg/L). The remaining 10 isolates possessed both an ESBL and KPC, with a mean cefiderocol MIC of 1.07 ± 1.19 mg/L (*p* = 0.07 compared with isolates lacking an ESBL, range = 0.06--4 mg/L). There was no correlation between cefiderocol MICs and expression of *bla*~KPC~, the efflux-related genes *marA*, *ramA*, *soxS*, and *acrB*, and the porin-related genes *ompK*35 or *ompK*36. Isolates with a frameshift mutation involving *ompK*35 had similar MICs as isolates without this mutation.

*P. aeruginosa* and *A. baumannii* {#s007}
----------------------------------

### Pseudomonas aeruginosa {#s008}

There were 269 isolates of *P. aeruginosa* gathered in the 2017 surveillance study ([Table 2](#tb2){ref-type="table"}), and 99.6% had a cefiderocol MIC ≤4 μg/mL. Compared with the isolates susceptible to ceftazidime, the nonsusceptible isolates had MIC~50~/MIC~90~ values for cefiderocol that were twofold higher (0.5/4 vs. 0.25/2 mg/L), but mean values were similar (0.84 ± 1.09 vs. 0.75 ± 1.15 mg/L, *p* = NS). There were 130 carbapenem-nonsusceptible isolates gathered in the 2013--2014 surveillance study, and the MIC~50~/MIC~90~ values were 0.5/1 mg/L.

###### 

Susceptibility Results Involving *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from the 2017 Surveillance Collection and the 2013--2014 Carbapenem-Resistant Collection of Isolates

                                                          MIC~50~   MIC~90~   Range                 
  ------------------------------------------------------- --------- --------- -------------------- ------
  2017 surveillance isolates                                                                       
   *P. aeruginosa* (*n* = 269)                                                                     
    Cefiderocol                                           0.25      0.5       ≤0.03 to 8           99.6
    Piperacillin/tazobactam                               8/4       128/4     2/4 to \>128/4       75
    Ceftazidime                                           4         32        1 to \>32            83
    Meropenem                                             1         8         ≤0.12 to \>8         76
    Gentamicin                                            2         8         0.5 to \>16          79
    Ciprofloxacin                                         0.25      \>4       ≤0.12 to \>4         69
  2013--2014 Carbapenem-resistant surveillance isolates                                            
   *P. aeruginosa* (*n* = 130)                                                                     
    Cefiderocol                                           0.5       1         ≤0.03 to 4           100
  2017 surveillance isolates                                                                       
   *A. baumannii* (*n* = 46)                                                                       
    Cefiderocol                                           0.25      1         0.06 to 4            100
    Piperacillin/tazobactam                               32/4      \>128/4   ≤0.25/4 to \>128/4   43
    Ceftazidime                                           8         \>32      ≤0.12 to \>32        54
    Meropenem                                             4         8         ≤0.12 to \>8         48
    Gentamicin                                            2         \>16      0.5 to \>16          70
    Ciprofloxacin                                         \>4       \>4       ≤0.12 to \>4         46
  2013--2014 Carbapenem-resistant surveillance isolates                                            
   *A. baumannii* (*n* = 78)                                                                        
    Cefiderocol                                           0.5       8         0.12 to \>32         88

There were 33 characterized isolates of *P. aeruginosa* ([Supplementary Table S2](#SD2){ref-type="supplementary-material"}). Isolates with increased expression of *ampC* (\>10 times control) had similar cefiderocol MICs compared with isolates without increased expression of this enzyme (0.67 ± 1.01 vs. 0.27 ± 0.23 mg/L, *p* = 0.2). By regression analysis, there was no correlation between cefiderocol MICS and expression of *ampC mexA*, *mexC*, *mexE*, *mexX*, and *oprD*.

### Acinetobacter baumannii {#s009}

There were 46 isolates of *A. baumannii* gathered in 2017, and all had cefiderocol MICs ≤4 mg/L. Compared with the isolates susceptible to ceftazidime, the MIC~50~ value for cefiderocol was twofold higher in the 18 ceftazidime-nonsusceptible isolates (0.25 vs. 0.12 mg/L). There were 78 carbapenem-resistant isolates gathered in 2013--2014, including 47 with *bla*~OXA-23-type~ β-lactamases. Overall, the MIC~50~/MIC~90~ values were 0.5/8 mg/L, which was identical to the subset of isolates with *bla*~OXA-23-type~ β-lactamases.

There were 34 isolates characterized of *A. baumannii* ([Supplementary Table S3](#SD3){ref-type="supplementary-material"}). Isolates with an SHV ESBL had significantly higher cefiderocol MICs than isolates without ESBLs (8.04 ± 11.58 vs. 0.86 ± 1.08 mg/L, *p* = 0.02). By regression analysis, there was no correlation between cefiderocol MICs and expression of genes encoding *ampC*, *bla*~OXA-51~, and the efflux systems *adeB* and *abeM*.

Discussion {#s010}
==========

The progressive and global spread of multidrug-resistant Gram-negative pathogens has led to increasingly difficult-to-treat nosocomial infections. Given the extremely limited treatment options currently available, novel therapeutic agents are urgently needed. Cefiderocol is a novel catechol-substituted siderophore cephalosporin with a broad spectrum of antimicrobial activity. Against *Enterobacterales*, MIC~90~ values of ∼0.5--1 mg/L have been reported, with \>95% being inhibited by ≤4 mg/L (the proposed breakpoint for cefiderocol).^[@B4],[@B6],[@B9],[@B10]^ Consistent with these reports, the *Enterobacterales* in our study had overall MIC~90~ values of 0.5 mg/L, and all were inhibited by ≤4 mg/L. In a study by Jacobs *et al.*, cefiderocol MICs were higher in *Enterobacterales* possessing an ESBL, carbapenemase, or AmpC-type β-lactamase compared with isolates lacking these enzymes.^[@B12]^ Our study also documented greater cefiderocol MICs in isolates of *E. coli* and *K. pneumoniae* that were cephalosporin resistant. The activity of cefiderocol has been reported to be maintained in *Enterobacterales* possessing a wide variety of carbapenemases, including KPC, NDM VIM, IMP, and OXA-48.^[@B5],[@B9],[@B10],[@B12]^ The activity of cefiderocol was maintained in all our KPC-producing *K. pneumoniae*, with 90% of the isolates being inhibited by ≤2 mg/L, consistent with other reports.^[@B10],[@B12]^

Cefiderocol has also been reported to have considerable activity against other Gram-negative pathogens. For *P. aeruginosa*, including carbapenem-resistant isolates, MIC~90~ values of 0.5--1 mg/L have been reported.^[@B4],[@B10],[@B12]^ In our study, 99.6% of our surveillance isolates had cefiderocol MICs ≤4 mg/L. MICs did not appear to be significantly affected by the development of cephalosporin or carbapenem resistance, consistent with findings reported elsewhere for *P. aeruginosa*.^[@B12]^ Similarly, for *A. baumannii* overall MIC~90~ values of 1--2 mg/L, and 8 mg/L for carbapenem-resistant isolates, have been reported.^[@B4],[@B10],[@B12]^ All our 2017 surveillance isolates, and 88% of our previous collection of carbapenem-resistant *A. baumannii*, were inhibited by ≤4 mg/L. For *A. baumannii*, cefiderocol MICs were unaffected by the presence of OXA-23, consistent with findings reported elsewhere.^[@B10]^ However, as with the *Enterobacterales*, we noted cefiderocol MICs were significantly higher in ESBL-possessing isolates of *A. baumannii*.

The catechol moiety in cefiderocol chelates free iron, enabling entry into bacteria through their iron transport system.^[@B25]^ As such, cefiderocol may evade porin-related bacterial mechanisms of antimicrobial resistance. Consistent with other reports, when our collection of characterized isolates of *K. pneumoniae* were examined, cefiderocol MICs were not significantly affected by alterations in the porins OmpK35 and OmpK36.^[@B3],[@B10]^ In addition, we found no correlation between cefiderocol MICs and expression of several efflux-related genes. For *P. aeruginosa*, overexpression of the MexAB-OprM efflux system had no effect on the activity of cefiderocol.^[@B3]^ Similarly, in our collection of characterized isolates of *P. aeruginosa*, we found no correlation between expression of several efflux systems or in expression of the porin *oprD*. Finally, when tested against our collection of characterized isolates of *A. baumannii*, no correlation was found between cefiderocol MICs and expression of the efflux genes *adeB* and *abeM*.

Our study reaffirms the activity of cefiderocol against a large number of Gram-negative pathogens, including multidrug-resistant isolates. However, our findings may not be generalized to other multidrug-resistant pathogens, because only a limited variety of carbapenemases was identified (*bla*~KPC~ in *Enterobacterales* and *bla*~OXA-type~ in *A. baumannii*). Given the limited options available for many resistant nosocomial pathogens, our findings support the continued development of this agent.
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